Showing results (51-60 of 76) with videos related to
Sort By:
Pageof 8
Journal of Clinical Lipidology|May 6, 2014
An assessment by the Statin Liver Safety Task Force: 2014 updateHarold Bays, David E Cohen, Naga Chalasani, et al.European Heart Journal Open|September 22, 2025
Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trialMamas A Mamas, Harold Bays, Runjia Li, et al.Lipids in Health and Disease|December 2, 2010
Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?Harold Bays, Scott Conard, Lawrence A Leiter, et al.The New England Journal of Medicine|July 22, 2010
Multicenter, placebo-controlled trial of lorcaserin for weight managementSteven R Smith, Neil J Weissman, Christen M Anderson, et al.The American Journal of Cardiology|November 26, 2008
Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart diseaseLawrence A Leiter, Harold Bays, Scott Conard, et al.Obesity Pillars|July 12, 2026
Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: Results from the PERCEPTIONS surveyTheresa Hunter Gibble, Harriet Makin, Claire Gerber, et al.Diabetologia|April 7, 2019
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING studyRobert S Rosenson, Martha L Daviglus, Yehuda Handelsman, et al.Journal of Lipid Research|April 22, 2009
Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in menThomas Sudhop, Michael Reber, Diane Tribble, et al.The American Journal of Cardiology|March 19, 2015
Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemiaChristie M Ballantyne, Joel Neutel, Anne Cropp, et al.Journal of Medical Economics|April 21, 2026
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trialErin Johansson, John P H Wilding, Navneet Upadhyay, et al.Pageof 8